Results for urea cycle defect livers translation from English to Maltese

about urea cycle disorders
dwar id-disturbi fiċ-ċiklu tal-urea

urea cycle disorders are rare.
disturbi fiċ-ċiklu tal-urea huma rari.

ammonaps is prescribed to patients with urea cycle disorders.
ammonaps jingħata bir-riċetta lil pazjenti bi problemi fiċ-ċiklu ta’ l-urea.

it is used to treat patients who have urea cycle disorders.
jintuża biex jikkura pazjenti li jkollhom disturbi fiċ-ċiklu tal-urea.

ammonaps is used to treat patients who have urea cycle disorders.
ammonaps jintuża għat-trattament ta’ pazjenti li għandhom disturbi fiċ-ċiklu tal-urea.

in urea cycle disorders, the body cannot remove the nitrogen from the protein that we eat.
f'disturbi fiċ-ċiklu tal-urea, il-ġisem ma jkunx jista’ jneħħi n-nitroġenu mill-proteina li nieklu.

ammonaps treatment should be supervised by a physician experienced in the treatment of urea cycle disorders.
il-kura permezz ta’ ammonaps għandu jkun sorveljat minn tabib b’esperjenza fil-kura ta’ problemi fiċ-ċiklu ta’ l-urea.

ammonaps treatment should be supervised by a doctor who has experience in treating patients with urea cycle disorders.
it-trattament b’ammonaps għandu jiġi ssorveljat minn tabib li għandu esperjenza fit-trattament ta’ pazjenti b’disturbi fiċ-ċiklu tal-urea.

in urea cycle disorders, the body is not able to produce enough liver enzymes to remove the extra nitrogen.
f'disturbi fiċ-ċiklu tal-urea, il-ġisem ma jkunx jista' jipproduċi biżżejjed enzimi tal-fwied biex ineħħi n-nitroġenu żejjed.

as a consequence, sodium phenylbutyrate reduces elevated plasma ammonia and glutamine levels in patients with urea cycle disorders.
bħala riżultat ta’ dan, sodium phenylbutyrate inaqqas il-livell ta’ ammonia għolja fil-plażma u ta’ glutamine f’pazjenti bi problemi fiċ-ċiklu ta’ l-urea.

it can only be obtained with a prescription and treatment should be supervised by a doctor who has experience in treating patients with urea cycle disorders.
il-mediċina tista’ tinkiseb biss b’riċetta ta’ tabib u l-kura għandha tiġi ssorveljata minn tabib li għandu l-esperjenza fil-kura ta’ pazjenti b’disturbi fiċ-ċiklu tal- urea.

ammonaps has been studied in 82 patients with urea cycle disorders who were treated with ammonaps and had not received other treatments for their disease before.
ammonaps ġie studjat fi 82 pazjent b’disturbi fiċ-ċiklu tal-urea li ġew trattati b’ammonaps u li ma kienux irċevew trattamenti oħrajn għall-marda tagħhom qabel.

the orally applied 13c-urea is metabolised to carbon dioxide and ammonia or is integrated into the body’s own urea cycle.
l-urea 13c meħuda mill-ħalq hija metabolizzata għal dijossidu karboniku u ammonia jew inkella tiġi integrata fiċ-ċiklu uriku tal-ġisem.

ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.
ammonaps hu intiż bħala terapija aġġuntiva fil-kura kronika ta’ disturbi fiċ-ċiklu ta’ l-urea, li jinvolvu nuqqas ta’ carbamyl phosphate synthetase, ornithine transcarbamylase jew argininosuccinate synthetase.

patients with urea cycle disorders cannot get rid of ammonia from the body, so it can reach high levels, leading to serious problems including disability, brain damage and death.
il- pazjenti b’disturbi fiċ-ċiklu tal-urea ma jistgħux ineħħu l-ammonia mill-ġisem, għalhekk din tista’ tilħaq livelli għoljin, u dan iwassal għal problemi serji inklużi diżabilità, ħsara fil-moħħ u mewt.

therefore, despite the limited information available, the chmp decided that ammonaps’s benefits are greater than its risks as adjunctive therapy in the chronic management of urea cycle disorders.
għalhekk, minkejja l-informazzjoni limitata disponibbli, is-chmp iddeċieda li l-benefiċċji ta’ ammonaps huma akbar mir-riskji tiegħu bħala terapija aġġuntiva fil-kura kronika tad-disturbi fiċ-ċiklu tal-urea.

based on studies of phenylacetylglutamine excretion in patients with urea cycle disorders it is possible to estimate that, for each gram of sodium phenylbutyrate administered, between 0.12 and 0.15 g of phenylacetylglutamine nitrogen are produced.
skond studji li saru b’phenylacetateglutamine, it- tneħħija mill-ġisem f’pazjenti bi problemi fiċ-ċiklu ta’ l-urea, hu possibli li jkun stmat li, għal kull gramma ta’ sodium phenylbutyrate mogħti, jiġi prodott bejn 0.12 u 0.15 g ta’ phenylacetylglutamine nitrogen.

the committee for medicinal products for human use (chmp) noted that urea cycle disorders are a serious disease with few treatments available, and that ammonaps has been shown to prevent ammonia levels becoming too high.
il-kumitat għall-prodotti mediċinali għall-użu mill-bniedem (chmp) innota li d-disturbi fiċ-ċiklu tal-urea huma marda serja bi ftit trattamenti disponibbli, u li ammonaps wera li jista’ jimpedixxi l- livelli ta’ ammonia milli jilħqu livelli għoljin wisq.

previously, neonatal-onset presentation of urea cycle disorders was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen- free analogues.
qabel, neonatal-onset presentation ta’ disturbi taċ-ċiklu ta’ l-urea kienu kważi universalment fatali fl- ewwel sena tal-ħajja, anke meta kkurata permezz ta’ dijaliżi peritonejali u b’ amino aċidi essenzjali jew l-analogi tagħhom li huma ħielsa minn nitrogen.

multi-centre prospective non-interventional registry in patients with urea cycle disorders on treatment with glycerol phenylbutyrate to characterise patients` demographics, and to document long-term safety and clinical outcomes
reġistru b’aktar minn ċentru wieħed prospettiv u mingħajr intervent f’pazjenti